Investors compare VanEck's PPH and Invesco's PJP to determine which pharmaceutical ETF delivers better value and exposure
Executive summary: A July 4, 2026 Yahoo Finance article compared VanEck’s PPH and Invesco’s PJP pharmaceutical ETFs, detailing their holdings, expense ratios and recent performance. The comparison helps investors allocate to the pharmaceutical sector and influences competitive dynamics between the two ETF providers.
Who is involved: VanEck, Invesco, retail and institutional investors, and ETF analysts.
Likely next: Market watchers will monitor fund flows for any shifts, and the providers may adjust fees or launch new thematic versions to capture assets.
The Yahoo Finance article breaks down the holdings, expense ratios and recent performance of VanEck’s Pharmaceutical ETF (PPH) and Invesco’s Pharmaceutical ETF (PJP), noting that PPH leans more toward large‑cap drug makers while PJP includes a broader mix of mid‑ and small‑cap companies. It highlights that PPH carries a slightly lower expense ratio but PJP has shown stronger year‑to‑date returns in the latest period. The piece concludes that the choice depends on an investor’s preference for cost efficiency versus broader sector exposure.
Timeline
- — Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP? (Yahoo Finance)
- — State Street Health Care ETF Tops Invesco Pharma on Cost and Size (Yahoo Finance)
Analysis — what this means
Likely next events
- Increased inflows into pharma ETFs if the sector rebounds
- Launch of new niche pharmaceutical or biotech ETFs
Sectors affected
- Pharmaceuticals
- ETF industry
- Healthcare investing
Historical parallels
- State Street Health Care ETF topped Invesco Pharma on cost and size (July 4, 2026)
- Banking ETF showdown: State Street’s KBE vs iShares’ IAT (July 4, 2026)
Key entities
Sources
Open the full interactive case file on Beyond →